1185 GENERATION OF SELECTIVE HIGH AFFINITY LIGANDS TO BLOCK CD81-LARGE EXTRACELLULAR LOOP: HEPATITIS C VIRUS–E2 GLYCOPROTEIN INTERACTION
2013
Background and Aims: HCV infects around 3.3% of the
world population. The standard of care HCV treatment
(Peginterferon/Ribavirin) leads to serious side effects and SVR is
<50% in genotype-1 patients. The newly FDA approved protease
inhibitors (Telaprevir/Boceprevir) were found to be effective when
each is combined with PR giving higher SVR rates in GT-1. However
the poor safety profile of TVR and BOC reported in the Week 16
analysis of the French Early Access Program suggest there is
still a need for better HCV drugs. Many companies have active
programs developing HCV protease and polymerase inhibitors. We
are developing drugs to block an earlier step in HCV infection, CD81
mediated invasion. In this study we are developing Selective High
Affinity Ligands (SHALs) to target the E2 binding site on CD81 and
block their interaction.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI